Patient perceptions of insulin detemir as reported through patient telephone surveys

Kerney, Donna; Paradis, Diana; Brunton, Stephen

doi:10.1185/030079907x219508

“…118 A telephone-based survey of 586 insulin detemir users found that patients associated the drug with improved awareness of blood glucose levels, increased confidence in glycemic control, increased confidence in avoiding hypoglycemia, avoidance of weight gain, and improved satisfaction with treatment versus prior insulins. 119 An analyses of a cohort of type 1 diabetes patients in Belgium who switched their basal insulin to insulin detemir in the PREDICTIVE study also reported a significant improvement in treatment satisfaction, 120 although it should be noted that this might have been a selfselected group in which there had been atypically poor performance of previous insulin regimens.…”

Section: Patient Quality Of Life and Treatment Satisfactionmentioning

confidence: 99%

Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics

Floch¹

2010

DMSO

View full text Add to dashboard Cite

Insulin detemir is an analog of human insulin designed to provide a long duration of basal insulin action. This is achieved by protracted absorption from the injection depot, which results in part from increased self-association of insulin detemir molecules and in part from reversible albumin binding. Subsequent albumin binding in the circulation is thought to buffer changes in the effects at target tissues that could otherwise arise from variability in absorption rate. In consequence, insulin detemir has shown a less variable pharmacodynamic profile than alternative basal insulins; this manifests as more consistent temporal glucose reduction profiles in repeat-clamp studies. In clinical trials, insulin detemir has been characterized by consistent risk reductions in hypoglycemia, as well as reduced weight gain in comparison with other basal insulins. Given some recent associations that have been made in prospective and epidemiologic studies between glucose variability and/or hypoglycemia and increased cardiovascular risk, and the long-known association between excess weight and cardiovascular risk, it is possible that the clinical profile of insulin detemir may carry prognostic value with regard to cardiovascular safety, although this is yet to be substantiated. There have also been some concerns raised recently over the use of insulin analogs and cancer risk, but available clinical data and the receptor interaction profile of insulin detemir suggest no excess in risk in comparison with human insulin therapy. Optimal approaches for the clinical use of insulin detemir have been emerging through an increasing clinical study base, and the analog is becoming established as a potentially valuable therapy option.

show abstract

“…A telephone-based survey of 586 insulin detemir users found that patients associated the drug with improved awareness of blood glucose levels, increased confidence in glycemic control, increased confidence in avoiding hypoglycemia, avoidance of weight gain, and improved satisfaction with treatment versus prior insulins 119. An analyses of a cohort of type 1 diabetes patients in Belgium who switched their basal insulin to insulin detemir in the PREDICTIVE study also reported a significant improvement in treatment satisfaction,120 although it should be noted that this might have been a self-selected group in which there had been atypically poor performance of previous insulin regimens.…”

Section: Patient Quality Of Life and Treatment Satisfactionmentioning

confidence: 99%

Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics

Floch¹

2010

DMSOTT

View full text Add to dashboard Cite

Insulin detemir is an analog of human insulin designed to provide a long duration of basal insulin action. This is achieved by protracted absorption from the injection depot, which results in part from increased self-association of insulin detemir molecules and in part from reversible albumin binding. Subsequent albumin binding in the circulation is thought to buffer changes in the effects at target tissues that could otherwise arise from variability in absorption rate. In consequence, insulin detemir has shown a less variable pharmacodynamic profile than alternative basal insulins; this manifests as more consistent temporal glucose reduction profiles in repeat-clamp studies. In clinical trials, insulin detemir has been characterized by consistent risk reductions in hypoglycemia, as well as reduced weight gain in comparison with other basal insulins. Given some recent associations that have been made in prospective and epidemiologic studies between glucose variability and/or hypoglycemia and increased cardiovascular risk, and the long-known association between excess weight and cardiovascular risk, it is possible that the clinical profile of insulin detemir may carry prognostic value with regard to cardiovascular safety, although this is yet to be substantiated. There have also been some concerns raised recently over the use of insulin analogs and cancer risk, but available clinical data and the receptor interaction profile of insulin detemir suggest no excess in risk in comparison with human insulin therapy. Optimal approaches for the clinical use of insulin detemir have been emerging through an increasing clinical study base, and the analog is becoming established as a potentially valuable therapy option.

show abstract

Patient Perspectives and Experience with Dalfampridine Treatment in Multiple Sclerosis-Related Walking Impairment: The Step Together Program

Crayton

¹

,

Sidovar

²

,

Wulf³

et al. 2014

Patient

View full text Add to dashboard Cite

BackgroundDalfampridine extended-release tablets (dalfampridine-ER; in Europe, prolonged-release fampridine, and elsewhere, fampridine modified or fampridine sustained release), 10 mg twice daily, are available for the treatment of improvement of walking in patients with multiple sclerosis, as demonstrated by an increase in walking speed. On-drug patient perspectives and experiences are valuable to understand and manage this patient population.ObjectiveThe objective of this study was to examine perspectives and experiences of patients receiving dalfampridine-ER in a real-world setting.MethodsStep Together, an ongoing program that captures real-world patient experience with dalfampridine-ER treatment, consists of a survey administered at baseline (before dalfampridine-ER initiation) and at 30 (first follow-up) and 60 days (second follow-up) after initiation. The survey includes modified versions of the 12-item Multiple Sclerosis Walking Scale (mMSWS-12) and the Sheehan Disability Scale (mSDS) to assess walking ability and functional impairment, respectively.ResultsAs of September 2013, 2,248 patients participated in the baseline survey and 522 completed both follow-up surveys (completers). Among the completers, improvements in walking ability and function relative to baseline were significant at both follow-ups as measured by mMSWS-12 and mSDS scores, respectively. Notably, 69–74 % of completers at both follow-ups had improved mMSWS-12 scores, with scores greater than the range considered to be minimally clinically significant. Patients who completed the program expressed satisfaction with overall dalfampridine-ER treatment, and 69 % indicated that the survey would help them communicate better with their healthcare providers.ConclusionResults highlight the utility of patient-reported outcomes in the assessment of patient perspective and experience, providing a useful supplement to traditional objective measures used in clinical studies.Electronic supplementary materialThe online version of this article (doi:10.1007/s40271-014-0102-z) contains supplementary material, which is available to authorized users.

show abstract

Patient perceptions of insulin detemir as reported through patient telephone surveys

Cited by 6 publications

References 20 publications

Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics

Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics

Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics

Patient Perspectives and Experience with Dalfampridine Treatment in Multiple Sclerosis-Related Walking Impairment: The Step Together Program

Contact Info

Product

Resources

About